The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
Abstract
BACKGROUND: It has been recognized for more than 20 years that the macrolides have immunomodulatory effects that are beneficial for those suffering from chronic pulmonary inflammatory syndromes, such as diffuse panbronchiolitis, cystic fibrosis, asthma and bronchiectasis. The macrolides have consistently been associated with decreased length of stay and mortality when used alone or in combination with beta-lactam antibiotics. This effect can be demonstrated against combinations consisting of beta-lactams and other antibiotics active against 'atypical chest pathogens' when treating community-acquired pneumonia (CAP) in hospitalized patients. As such, it appears that the macrolides' effects in CAP patients are more than just antibacterial in nature. AIMS OF THIS REVIEW: This review aims: to give the reader information on the background areas described, as well as related areas; to review the CAP benefits with macrolides and how they may be related to the immunomodulatory properties they demonstrate, albeit in a shorter period of time than previously demonstrated with chronic pulmonary disorders; to use ex vivo data to support these extrapolations. LITERATURE SEARCH: A literature search using Medline was conducted from 1966 onwards, searching for articles with relevant key words such as macrolide, diffuse panbronchiolitis, community-acquired pneumonia, biofilm, immunomodulation, cystic fibrosis, erythromycin, clarithromycin, roxithromycin and azithromycin, bronchiectasis and asthma. When appropriate, additional references were found from the bibliographies of identified papers of interest. Any relevant scientific conference proceedings or medical texts were checked when necessary. CONCLUSIONS: (1) Research into macrolide immunomodulation for chronic pulmonary disorders demonstrates consistent positive effects, although of types other than seen with diffuse panbronchiolitis. These effects, together with their inhibitory activity on biofilms, have the potential to make them a useful option. (2) The benefits for CAP are consistent, and higher when a macrolide is given with another atypical agent than if the other atypical agent is given alone, suggesting a non-antibacterial benefit. (3) Recent research of the immunomodulatory properties of azithromycin imply that azithromycin may have a previously unknown short-term biphasic effect on inflammation modulation: enhancement of host defence mechanisms shortly after initial administration followed by curtailment of local infection/inflammation in the following period. (4) Additional in vivo research is needed prior to developing any firm conclusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Musher, D. M., & Fine, M. J. (2000) · Clinical Infectious Diseases · doi:10.1086/313954 · Cited by 2,286
Mandell, L. A., Bartlett, J. G., Dowell, S. F., File, T. M., Musher, D. M., & Whitney, C. (2003) · Clinical Infectious Diseases · doi:10.1086/380488 · Cited by 1,004
Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell III, P. W., et al. (2003) · JAMA · doi:10.1001/jama.290.13.1749 · Cited by 958
Quality of Care, Process, and Outcomes in Elderly Patients With Pneumonia
Meehan, T. P. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550230056037 · Cited by 919
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Heffelfinger, J. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.10.1399 · Cited by 610
Improvement of Survival in Patients with Diffuse Panbronchiolitis Treated with Low-dose Erythromycin
KUDOH, S., AZUMA, A., YAMAMOTO, M., IZUMI, T., & ANDO, M. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9710075 · Cited by 582
Equi, A., Balfour-Lynn, I., Bush, A., & Rosenthal, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11081-6 · Cited by 543
Wolter, J. (2002) · Thorax · doi:10.1136/thorax.57.3.212 · Cited by 518
Gleason, P. P., Meehan, T. P., Fine, J. M., Galusha, D. H., & Fine, M. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2562 · Cited by 496
Cited by
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Dowell, S. F., File, T. M., Musher, D. M., Niederman, M. S., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511159 · Cited by 6,202
British Thoracic Society guideline for non-CFbronchiectasis
Pasteur, M. C., Bilton, D., Hill, A. T., & on behalf of the British Thoracic Society Bronchiectasis (non-CF) Guideline Group (2010) · Thorax · doi:10.1136/thx.2010.136119 · Cited by 1,046
Exploiting Quorum Sensing To Confuse Bacterial Pathogens
LaSarre, B., & Federle, M. J. (2013) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00046-12 · Cited by 820
Azithromycin: Mechanisms of action and their relevance for clinical applications
Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.003 · Cited by 661
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Robert, C., Soria, J.-C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., Wechsler, J., Lhomme, C., Escudier, B., Boige, V., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70243-6 · Cited by 554
Long-Term Follow-Up and Outcome of a Large Cohort of Patients with Common Variable Immunodeficiency
QUINTI, I., SORESINA, A., SPADARO, G., MARTINO, S., DONNANNO, S., AGOSTINI, C., CLAUDIO, P., FRANCO, D., MARIA PESCE, A., BORGHESE, F., et al. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9075-1 · Cited by 536
A comprehensive review of glycosylated bacterial natural products
Elshahawi, S. I., Shaaban, K. A., Kharel, M. K., & Thorson, J. S. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00426d · Cited by 439
COVID-19: A Multidisciplinary Review
Chams, N., Chams, S., Badran, R., Shams, A., Araji, A., Raad, M., Mukhopadhyay, S., Stroberg, E., Duval, E. J., Barton, L. M., et al. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00383 · Cited by 386
Antimicrobial resistance in low- and middle-income countries: current status and future directions
Sulis, G., Sayood, S., & Gandra, S. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1951705 · Cited by 379
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?
Brown, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4675 · Cited by 359
Jensen, J. S., Bradshaw, C. S., Tabrizi, S. N., Fairley, C. K., & Hamasuna, R. (2008) · Clinical Infectious Diseases · doi:10.1086/593188 · Cited by 338
Zarogoulidis, P., Papanas, N., Kioumis, I., Chatzaki, E., Maltezos, E., & Zarogoulidis, K. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1161-x · Cited by 299
Clement, A. (2006) · Thorax · doi:10.1136/thx.2005.057950 · Cited by 292
Narita, M. (2010) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-010-0044-x · Cited by 279
Sulis, G., Batomen, B., Kotwani, A., Pai, M., & Gandra, S. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003682 · Cited by 117
Metadata
- Authors
- Amsden, G. W.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-01
- Volume
- 55
- Issue
- 1
- Pages
- 10-21
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2152733931
- Cited by
- 409
- References
- 33
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.